Lack of reversibility for NOACs
[first paragraph of article]
I read with interest the recent discussion on the ENGAGE-AF trial written by Kaba et al. The authors provide a comprehensive discussion of the novel oral anticoagulant (NOAC), Edoxaban. However, it is important to remind the readers that although NOACs are being promoted as first line for stroke prevention in atrial fibrillation, there is considerable risk of bleeding associated with their uses and no reliable reversible agent is available.
Letters to the editor
This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.